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Abstract (234/250 Words) 
 
Medication non-adherence, defined as any deviation from the regimen recommended by their 
healthcare provider, can increase morbidity, mortality, and side effects, while reducing 
effectiveness.  Through studying two respiratory conditions, asthma and tuberculosis (TB), we 
thoroughly review the current understanding of the measurement and reporting of medication 
adherence.   
 
In this paper, we identify major methodological issues in the standard ways that adherence has 
been conceptualised, defined and studied in asthma and TB. Between- and within- the two diseases 
there are substantial variations in adherence reporting, linked to differences in dosing intervals and 
treatment duration. Critically, the communicable nature of TB has resulted in dose-by-dose 
monitoring becoming a recommended treatment standard.  Through the lens of these similarities 
and contrasts, we highlight contemporary shortcomings in the generalised conceptualisation of 
medication adherence.   Furthermore, we outline elements in which knowledge could be directly 
transferred from one condition to the other, such as the application of large-scale cost-effective 
monitoring methods in TB to resource-poor settings in asthma. 
 
To develop a more robust evidence-based approach, we recommend the use of standard 
taxonomies detailed in the ABC Taxonomy when measuring and discussing adherence. Regimen 
and intervention development and use should be based on sufficient evidence of the commonality 
and type of adherence behaviours displayed by patients with the relevant condition. A systematic 
approach to the measurement and reporting of adherence could improve the value and 







Medication adherence is defined as the process by which a patient takes their medication, 
compared to the regimen recommended with their healthcare provider.  The World Health 
Organization (WHO) describes the dimensions affecting adherence in five interacting categories: 
the health system, the condition, the treatment regimen, the socioeconomic environment, and the 
patient themselves 1.  Many frameworks have detailed the resulting barriers, including forgetting, 
incapacity (such as being unable to self-administer, or financial constraints), incorrectly 
interpreting instructions, deviating from the regimen due to beliefs about the necessity or safety of 
a treatment, health systems’ factors and a lack of social support 1–5.  Non-adherence is associated 
with poor clinical outcomes 6–11, and contributes towards the emergence of drug-resistant 
infections 12–14.  It may lead to unnecessary dose escalation and/or additional treatment to control 
symptoms, itself resulting in the onset of avoidable side-effects 15–19.  Non-adherence may also 
result in adverse events related to discontinuation 20–22 or re-initiation 23,24. Furthermore, increased 
expenditure is incurred through preventable unscheduled primary and secondary care engagement 
(including primary care consultations and emergency department presentation), and wasted 
medication 18,25–31.  The burden of non-adherence in chronic diseases is high (around 50%) 1, and 
the prevalence is highest in those with polypharmacy and comorbidities 32,33. 
 
Measuring adherence is vital for estimating associated costs (both financial and quality of life) 
28,34,35, identifying people who are most at-risk during their treatment regimen, undertaking 
targeted intervention development 36–38, and accurately assessing the impact of novel interventions 
39,40.  A substantial challenge in adherence measurement is that the field is not standardized and 
different measures have been introduced, the comparability of which is typically unclear 41–43.  To 
address this lack of uniformity in definitions, and the inherent complexity of adherence data, in 
2012 Vrijens et al. proposed a new taxonomy (called ABC) for describing adherence in three 
phases: initiation, implementation, and persistence 51.  As shown in Figure 1, treatment is initiated 
at the first dose taken of a prescribed medication and discontinued at the last dose taken.  
Implementation describes the agreement between the patient’s dosing regimen and the prescribed 
regimen, in the period between initiation and discontinuation.   Persistence, the continuity of 
treatment, describes the duration and incidence of unscheduled intermissions (an extended 
duration of consecutively missed doses, with the minimum duration varying by treatment and 













Figure 1: Diagram highlighting the three phases of medication adherence in the ABC taxonomy, relative to patient-level 
prescription events. 
 
There are multiple pharmacokinetic mechanisms which influence a medication’s forgiveness (the 
number of doses that can be skipped without decline in therapeutic effect) 49.  These include storage 
elsewhere in the body to the target organ in a releasable manner, that their effect is delayed 
compared to the concentration in the blood, that the dose strength is sufficiently high that a small 
decrease would result in only a minor change in effect, or that medication has a long elimination 
half-life (the time by which approximately half of the medication has left the body).   
 
In this study, we review the methods employed for measuring and reporting adherence in two 
respiratory diseases, tuberculosis (TB) and asthma.   TB and asthma both have high disease burden 
50,51 and apparently prevalent non-adherence  7,52–54, but differ substantially in their drug delivery 
method and treatment time scale, and their global hotspots.  By comparing and contrasting 
procedures in these two very different conditions, we highlight the similarities and transferable 
lessons which are masked by differences in adherence conceptualisation when confined to the 
investigation of either disease.  By applying a standard taxonomy, greater awareness into these 
parallels is facilitated, and research can be conducted with greater efficiency and rigour.  The key 
aims of the study were to gain insights into: a) the generalised conceptualisation of adherence 
assessment; and b) how adherence comparison between and within conditions should be 
approached.  
 
Background: Pathophysiology, Epidemiology, and Treatment 
 
Asthma 
Asthma is a chronic disease that is characterised by hyper-responsiveness to stimuli, leading to 
inflammation which restricts airflow and thus oxygen supply.  When poorly controlled ,even mild 




of symptoms, which without treatment result in loss of consciousness and, eventually, death 56.  
Asthma has been estimated to affect between 235 and 339 million people worldwide 50,57.  The UK 
is amongst the countries with the highest prevalence 58 and asthma was listed as the primary cause 
of 3.8 deaths per day in 2015 59.    
 
Most medications for controlling asthma are taken twice each day by inhalation.  Asthma therapy 
follows a fairly linear path, stepping up dosage of controller medications when necessary or 
incorporating add-on therapies 60.  Asthma treatment is required for most patients to be taken 
continuously after diagnosis, for the patient’s entire life.  Recent evidence indicates that asthma is 
forgiving to poor therapy adherence, and that it is possible to achieve similar level of exacerbation 
reduction in mild asthma with less frequent doses of inhaled steroids than are typically prescribed 
61. Given that drug effects may persist for several days after administration 62, asthma medications 
with longer durations of efficacy may be particularly forgiving 63–65.  Importantly, the same 
medication may also be eliminated at different rates in different people (known as pharmacokinetic 
variability), based on factors such as age, sex, smoking status and body size 66–68.   
 
Tuberculosis 
TB primarily manifests as a pulmonary condition, although disease also occurs at other bodily sites 
69. Symptoms are generic and include fever, tiredness and weight loss. Individuals with pulmonary 
disease may have a persistent and productive cough (including haemoptysis).  TB remains in the 
top 10 causes of death globally 70; in 2018, 1.5 million people died of the disease 51. In the absence 
of treatment, approximately 30% of patients die within 18 months of diagnosis, 30% spontaneously 
self-cure, and 40% remain sputum smear positive 71.  The incidence of TB is unevenly distributed, 
with eight countries bearing two-thirds of the burden (Bangladesh, China, India, Indonesia, 
Nigeria, Pakistan, the Philippines, South Africa) and India alone accounting for 27% (2018).  Most 
of the highest ranking countries by incidence rates are in southern and central Africa 72. 
 
Treatment for TB is time-limited and depends upon the presence and extent of drug resistance in 
the underlying infecting strain(s).  Drug sensitive disease is treated for six months 73, while multi-
Drug Resistant (MDR) disease treatment is extended to between nine and 20 months 74.  WHO 
recommends that treatment for drug sensitive TB is administered once daily 75, although in some 
settings less-forgiving thrice weekly regimens are utilised to allow for the direct observation of 
treatment. Dosing of regimens for drug resistant disease can be complex (multiple doses per day 










Applications of the ABC Taxonomy 
 
Asthma 
The first phase of the ABC taxonomy, initiation, is simply defined in asthma as the first 
administered dose (including inhaler actuation, nebulising solution inhalation, monoclonal 
antibody injection, and more).  Treatment initiation is a great opportunity for healthcare providers 
to promote good adherence, and to train patients how inhalers should be used.   
 
Implementation, the second phase, is more multi-faceted.  There are a number of steps to the 
correct usage of an inhaler 38, such as allowing the chamber to refill between consecutive doses.  
Incorrect technique contributes towards a lower than desired volume of medication ingested and 
can be considered a component of adherence.  Furthermore, inhaled corticosteroids are usually 
required to be taken once or twice a day and for twice-daily regimens the two doses should be 
roughly 12 hours apart in the morning and evening.   
 
Dose interval length for other maintenance treatments, including LABAs and add-on therapies 
such as allergy treatments and biologicals, vary greatly.  For example, some monoclonal antibody 
treatments such as omalizumab are only administered at four-weekly intervals 78–80.  Relievers are 
taken only as needed to relieve heightened symptoms, or as a short-term preventative measure 
(such as before exercise 81,82).  Although, as previously discussed, inhaled asthma medications are 
usually taken every day, it is becoming more common to recommend patients self-manage their 
treatment to some extent, and use their inhaler only as needed 61,83,84.  For those patients where the 
inhaler use is not following a systematic prescribed pattern, it is not meaningful to measure their 
adherence to their regimen.  Medication usage patterns, however, can still be measured and 
reported in the same way, as they can provide data to inform studies predicting the risks of clinical 
outcomes.   
 
Due to the unbounded duration of treatment for asthma, there are many opportunities for 
discontinuation and re-initiation.  Treatment may be discontinued by a healthcare provider 
following a revised diagnosis, a change in regimen, or resolution of the condition (such as in 
childhood asthma 85 and occupational asthma 86).  Unsanctioned discontinuation is also common 
87.  Periods of non-persistence can be analysed to understand what triggers their occurrence, as 
well as what triggers subsequent re-initiation 42.    
 
Tuberculosis 
Delayed initiation of treatment in TB is problematic in two fronts. First, bacteria have an extended 
time to replicate, thus increasing a patient’s bacterial load and potentially the severity of disease. 
Secondly, this allows a greater window of time in which transmission of infection can occur. Given 
the global prevalence of drug resistant TB 51, it is important to test for drug resistance before 




regimen. Without this, a regimen may not only fail to cure the patient, but the bacteria may 
additionally gain further drug resistance. 
 
Unlike in asthma, the standard regimen for drug sensitive TB consists of oral pills and thus 
technique in taking medications is of lesser concern. Fixed Dose Combination (FDCs) pills (of up 
to all four drugs in the initiation phase and both drugs in the continuation phase) are recommended 
by WHO to reduce pill burden 74. Patients using FDCs are therefore non-adherent to all drugs when 
they miss a dose of treatment. Due to drug absorption characteristics, patients are generally advised 
to take their medication on an empty stomach. The number and type of drugs for drug resistant 
disease means that dosing becomes more complex; administration technique can then become 
more important e.g. for injectable medications. In complete contrast to asthma, antibiotics are 
never taken ‘as needed’.  
 
Surveillance reporting of treatment outcome data to WHO has resulted in a set of standardised 
definitions that capture part of medication discontinuation, in the form of Loss to Follow-Up (LFU) 
88. LFU (previously called default) is defined as a break in treatment of two months or more, often 
measured by patients failing to appear for medical appointments, or to collect their drugs. This can 
include non-initiation. The risk of developing drug resistance means that (unsanctioned) drug 
holidays are not permitted in TB, although short intermissions (e.g. due to side effects) can be 
provider-sanctioned.   Although it is possible for patients to have discontinued treatment and still 
be attending appointments (and vice versa, to have disappeared from their original clinical care 
provider, but still be taking medication obtained from another source or a reserve of drugs), LFU 
remains an important source of non-adherence to TB treatment. Work in both drug sensitive and 
MDR TB has documented the prevalence and temporality of LFU 89,90. 
 
The time-bounded nature of TB treatment means that, unlike for asthma, discontinuation without 
subsequent re-initiation is possible i.e. a patient may discontinue treatment close enough to the end 
of their regimen, and display sufficient recovery, for treatment not to need to be re-started. 
 
 
Adherence Measurement  
 
Asthma  
Asthma medication adherence can be measured using pharmacy refill records, either aggregated 
to a single summary statistic over an extended duration (such as a clinical trial, or a single year) 
such as the medication possession ratio, or as a time-series such as the continuous measure of 
medication gaps  41–43.  Prescription recording systems cannot record whether a medication is 
actually taken.  As such, they can be considered a good estimator of treatment initiation and 




regimen 84.  They can, however, flag cases of over-use of reliever medication, which may be 
indicative of poor asthma control and/or poor controller adherence.   
 
Adherence can also be measured by patient self-report, such as asthma diaries, standardized 
questionnaires, and psychometric scales 84.  While many scales are intended for use across multiple 
medical conditions, there are asthma specific scales such as the Medication Intake Survey – Asthma 
(MIS-A) 91, Medication Adherence Report Scale for Asthma (MARS-A) 92,93,  and the Brooks et 
al. scales for inhaled and oral asthma medications94, respectively.  Depending on their structure, 
however, they may be able to capture all three phases of the ABC taxonomy.  For example, the 
MIS-A looks at the proportion of time with both correct dosing (implementation) and the 
proportion of weeks with at least some medication use (persistence) 91, however it does not 
explicitly cover non-initiation.    Estimates of implementation can also be made using inhaler 
technique assessment checklists 38, as poor inhaler technique to known to result in suboptimal drug 
delivery 95.   
 
Digital Adherence Technologies (DATs), are digital systems to aid in the measurement and 
management of medication adherence.  Electronic Monitoring Devices (EMDs) are DATs which 
directly and automatically measure the time and date of a dose being taken 96.  Smart inhalers, for 
example, are devices (or additions to existing devices) which collect data on inhaler usage and can 
transmit data (e.g. using Bluetooth) to a linked application on the user’s mobile device 97,98.  EMDs 
are highly accurate, as they directly measure the dispensation of medication, do not aggregate 
across medication refill periods (i.e. dose-by-dose data are available), and are far less subject to 
sources of measurement error 99,100.  When inhaled medication monitoring is conducted overtly, 
however, there is the potential for ‘dose dumping’; deliberately actuating multiple consecutive 
times in order to conceal poor adherence 101.  Many EMDs have functionality which allows these 
episodes to be detected; such as flagging occurrences of over a certain number of actuations in a 
short time duration 102, particularly when they occur soon before clinic or trial assessments 103.  
Furthermore, some  inhalers are able to provide feedback on inhaler technique, using sensors or 
audio segmentation to identify individual actions that comprise the correct usage instructions (such 
as shaking the cannister, and holding breath after actuation) 84,104.    
 
Adherence to asthma medication regimens can also be measured directly for some medications 
using biochemical measurements reflecting the amount of medication ingested (including hair, 
urine and blood samples) 105–109, and device monitoring such as canister weighing 110.    A lack of 
detectable medication in biological samples would imply either non-initiation or discontinuation, 
depending on the time-scale, and the expected to observed medication quantities could be used to 
estimate roughly implementation. 
 
Directly Observed Therapy (DOT), which entails a trained third-party (including doctors, nurses, 




asthma treatment; usually in children.  DOT enables treatment persistence to be measured, as well 
as implementation components such as timing, technique and dosage.  Schools have been 
identified as viable settings for supervised asthma therapy administration, as multiple children 
could be monitored consecutively or concurrently 111.  In adults, DOT is fairly impractical for daily 
medications, such as most inhaled asthma medications.  However, DOT has been suggested as an 
intervention to improve adherence in new biological asthma therapies, which may be delivered at 




Where such data are available (i.e. the formal healthcare sector), adherence to anti-TB regimens 
can also be measured indirectly through pharmacy refill records (typically on a monthly basis) or 
patient-reported outcome measures (such as the TB Medication Adherence Scale 113; TBMAS), 
and directly e.g. through urine or blood testing 114. The use of the WHO recommended strategy of 
DOT to ensure adherence to treatment means, however, that this is the most widely available 
source of information 115. Direct observation means that information on the consumption of each 
dose of treatment is recorded (particularly during the intensive phase), providing an exceptionally 
granular data source of all domains of adherence.  
 
Recent technological advances have resulted in a variety of DATs to measure adherence to anti-
TB treatment, as reviewed by Subbaraman et al. 116. These fall into five major categories, all of 
which document treatment-taking individually for each dose: 1) digital pillboxes, a type of EMD, 
which monitor and record each time that they are opened, and can also use sound or light effects 
as reminders, 2) 99Dots, where dispensing a dose of TB medication from the blister pack reveals 
an unpredictable toll-free number, to which the patient places a call, 3) Short Message Service 
(SMS) systems, where patients confirm that they have taken their medication by sending a message 
to their healthcare provider, 4) video DOT, which allows individuals to take their treatment without 
the proximal presence of an observer and can be synchronous or asynchronous, and 5) ingestible 
sensors, which are placed within pills and send a signal to a monitor worn by the patient, which is, 













Table 1: Direct and indirect adherence measurement in asthma and tuberculosis 
 Asthma Tuberculosis (TB) 
Pharmacy Refills Aggregate measures of when medications are collected from the 
pharmacy  
DOT Uncommon  World Health Organization 
recommends DOT; digital 
version video DOT 
Biochemical 
Measurements 
Presence of medication in urine, blood, or hair 
Electronic 
Monitoring Devices 
Predominantly smart inhalers 
(Inhaled asthma medications)  
Predominantly Electronic 
Pillboxes and ingestible sensors 
Patient Self-Report Asthma medication diaries, 
psychometric scales, and 
questionnaires such as MIS-A 
and MARS-A 
Questionnaires such as the 
TBMAS, and (real-time) SMS 
based reporting systems 
DOT: Directly Observed Therapy, SMS: Short Messaging System, TB: tuberculosis, MIS-A: 
Medication Intake Survey – Asthma, MARS-A: Medication Adherence Report Scale for Asthma, 






Many epidemiological and intervention studies still describe medication adherence using only a 
single measure (typically implementation related), often aggregated over an extended duration, 
such as percentage of days on which the prescribed doses of inhaled corticosteroids were taken 
7,110,118,119.  Indeed, Normansell et al.’s recent Cochrane review of asthma adherence interventions 
38 reported: 
“Almost all included studies reported some measure of adherence, usually as a percentage, with 
100% showing complete adherence, but the way in which this was captured and calculated 
varied between studies.” 
 
In a 2015 review of 23 studies looking at the association between adherence and risk of asthma 
attacks, Engelkes et al. found that only 3 (13%) used more than one measure 7.   As asserted by 
Boissel et al. 49: 
“One challenge in studying varying compliance […] is that no single feature can express it.” 
Of the studies in the Engelkes et al. review, five used the Medication Possession Ratio (MPR), 
defined as the total number of day’s supply for all refills in a particular time period, divided by the 
duration of the period, for controller medications (ICS, LABA or ICS+LABA combination 




Morton et al.’s review of asthma EMD studies in children found the mean ranged between 34 and 
73% 120.   Asthma subtypes may also contribute towards this variation in results, even within 
adherence measurement methods, however poor adherence has been reported even in those with 
severe asthma 121,122.  Ismaila et al. assessed two dimensions of adherence within their pharmacy 
claims data analysis: implementation according to the medication possession ratio (dichotomised 
at 80%), and persistence defined as continuously renewing prescriptions without a gap of more 
than 30 days 123.  They found that 42.7% of the patients (all on ICS+LABA therapy, N=19126) 
were compliant, and only 29.3% were persistent.  Persistence was strongly associated with all 
outcomes in adjusted analyses, but severe outcomes such as ICU admission and intubation were 
not associated with implementation.   
 
Many studies have aggregated their data even further; using binary thresholds of adherence  to 
benchmark individuals and to dichotomise a sample into good and poor adherers, commonly 80% 
9,52,111,124.   Both Gamble et al. 121 and Makhinova et al. 125 used a cut-off of 50%, with the latter 
noting that using an 80% threshold instead would have reduced the number of adherent individuals 
from 14.9% (of their population of over 30,000) to only 4.1%.   
 
While researchers are often still able to show clinical effect with single, aggregated measures, 
identifying and understanding the nuances of medication-taking is important, potentially aiding 
the effective intervention design to target the most harmful non-adherence patterns.   Furthermore, 
due to the long-term nature of treatment for chronic conditions such as asthma, and particularly 
the variability in airway responsiveness over a short period, measuring adherence aggregated over 
an extended duration of treatment is insufficient.  As noted by Alleman et al. 126:  
“Some temporal sequences of deviations from the prescribed regimen may be more detrimental 
to treatment effectiveness and safety compared to others.” 
It is vital to consider the time-varying, multi-dimensional, elements of adherence.  This may be 
simply measured as the variation in measures between intervals (such as prescription refills, or 
years of age), or as a moving average measure 126,127.   
 
Regarding inhaler technique, adherence is typically reported as binary indicators of whether 
specific errors (such as patients forgetting to tilt their head) were made 128–130, reported either 
individually or as a proportion or sum.  A recent study by Price et al. examined the effect that each 
error in isolation had on asthma control (stratified by inhaler device) 128.  They found that failing 
to breath out before inhalation was a common error in metered dose inhalers (25.4% prevalence) 
and resulted in 1.9 times higher odds of uncontrolled asthma than when that error was averted.  
The most compromising error was failing to remove the cap of the inhaler, but fortunately that was 
a rare occurrence (prevalence 0.4%). Finally, some studies simply rate technique categorically, 







Classical approaches to assessing adherence to anti-TB treatment have focussed on determining 
the proportion of patients taking greater than or equal to 80% or 90% of their daily doses 131–134. 
Exceptions to the use of simple percentage thresholds are included in the work of Podewils et al. 
and Bastard et al. 135,136, both of whom looked at the implications of different intermission lengths 
on treatment outcomes.  Although the weight of evidence is in favour of patients below these 
thresholds having a greater likelihood of a negative treatment outcome (for example, see the 
studies of Imperial et al. and Kayigamba et al.) 137,138, the deployment of DATs on a large scale 
provides substantial opportunities to provide greater insights into the relationship between 
adherence patterns and treatment outcomes 139. 
 
Estimates of the prevalence of adherence to anti-TB medication vary substantially globally. For 
example, in a study in south-eastern Malawi between 2007 and 2008, 35.1% of smear positive 
pulmonary TB patients aged 18 years or over and treated for six months were assessed to not have 
been fully adherent, based on treatment card data (documentation of directly observed dosing; 
during the continuation phase of treatment cards were held by the patients) 52. By comparison, in 
Kosovo in 2012, among all TB patients, 14.5% were estimated to have not taken their TB drugs 
for more than three days, (self-reported data) 54.    
 
Similarly to asthma, the time-varying nature of dose-by-dose adherence has not been sufficiently 
explored. In a recent study, Stagg et al. mapped adherence patterns across the entire treatment 
duration for a population of pulmonary disease patients in China 53. Within the cohort, 95.9% of 
patients were found to have missed at least one dose of treatment in a thrice weekly regimen; 
14.4% had discontinued by four months. Critical for intervention design, early-stage suboptimal 
implementation was associated with increased discontinuation rates.  
 
Cross-Comparison of Measurement and Reporting Methods between TB and Asthma 
 
There are a number of similarities in adherence measurement and reporting in TB and asthma.  
Firstly, methodological assessment is similar in terms of measurement, such as pharmacy refill 
measurements, EMDs, and patient self-report (see Table 1).  Secondly, it is common in both 
conditions for adherence to be aggregated over an extended duration, and even categorised or 
dichotomised in reports.  There are, however, several key differences to consider when comparing 
adherence in asthma and TB.  Firstly, asthma medications are prominently delivered using an 
inhaler which can be mis-used, resulting in poorer adherence than a patient may intend, or even 
realise.   
 
Secondly, dose-by-dose monitoring methods, such as DOT, are more common in TB than in 
asthma due to the shorter treatment timescale in TB (better feasibility).  In asthma, the financial 




the return on investment would be very low to implement at a population level.  There is also a 
higher cost-incentive for such a high resource measurement method in TB, as poor adherence leads 
to an increased risk of subsequent transmission, including strains with secondary, adherence-
induced, drug resistance.  
 
Finally, adherence is more complicated to conceptualise and define when treatment includes 
multiple medications (known as polypharmacy).  Polypharmacy is more common in asthma than 
TB, and often includes medications of different formulations (such as inhalers, nebules, and 
tablets) which are taken at different times of the day.  While adherence in asthma is commonly 
considered to be solely related to controller medication (typically either ICS or ICS+LABA 
medications, or sometimes with the addition of stand-alone LABA medications), the variation 
between adherence to these medications and add-on therapies such as LAMAs is less examined.  
In asthma, it has been found that higher numbers of prescribed medications can result in lower 
overall adherence 140, particularly in elderly and cognitively impaired patients 141.  In TB, an area 
of polypharmacy is the intersection with HIV and therefore antiretrovirals; approximately 8.6% of 





In this paper, we have compared the measurement and reporting of medication adherence in depth 
across two exemplar respiratory diseases, asthma and TB.  Commonalities in the conceptualisation 
of adherence between the two conditions, which are commonly overlooked due to their more 
elementary differences, become harder to compare due to differences in measuring and reporting 
procedures.  In examining these commonalities more closely, we can demonstrate the benefits of 
standardised terminologies and practices.   
 
We assert that, despite the established differences, it is possible to cross-reference protocols for 
assessments, treatments, and inform best practices between the asthma and TB communities.  For 
example, DOT could be easily applied to the rapidly expanding field of asthma biologics 
adherence.  Such treatments require less frequent administration, and are starting to transition from 
the hospital setting to the home environment thank to new auto-injectors.  Guidelines to 
overcoming barriers to DOT could be translated from TB to asthma to develop systems-level 
approaches to improve adherence in those with the highest likelihood of non-adherence to such 
treatments.  Similarly, if continued efforts to develop inhalation TB therapies 142 are fruitful, 
delivery vehicles could be designed using the knowledge of common asthma inhaler technique 
errors.    
 
We can also transfer learnings from other, non-respiratory, diseases in the same way.  One disease 




substantial discussion on the adherence levels required for sufficient viral suppression and how 
this varies from regimen to regimen 143. Similar levels of evidence should be the norm for other 
conditions, to aid both clinical approaches to adherence (when to intervene) and to determine how 
much should be invested in monitoring of drug-taking worldwide. 
 
We also see common examples of poor research practice reoccurring across different conditions, 
including excessive aggregation and categorisation, which mask substantial variations in 
medication taking behaviour 126, such as temporal changes in adherence across seasons, during 
school holidays, at weekends, after events such as treatment reviews, or with worsening symptoms.  
Many studies have used a binary threshold of 80% adherence  to benchmark individuals and to 
dichotomise a sample into good and poor adherers 52,111,124.   Indeed, Andrade et al. reported that 
in 136 studies of adherence using routine medical data, 38 used some dichotomisation, and 75% 
of these used the 80% threshold 42.   These studies covered therapeutic areas including migraines, 
cancer, diabetes, and incontinence.    
Rationale for this threshold was often lacking an evidence base, such as that by Murphy et al. 9:  
“We feel that 80% is a sensible cutoff because it allows for realistic expectations of patient 
behaviour while ensuring clinical efficacy of the drug.” 
Some people hypothesise the existence of an adherence threshold, above which the therapeutic 
effect of a drug is maintained, however, Stuaffer et al. demonstrate that the adherence threshold 
varied greatly even between drugs of the same class (40-80%) 65.  Furthermore, Morrison et al. 
have shown that the conceptual adherence threshold only holds assuming that doses are not missed 
consecutively for a longer duration than some drug-specific threshold 144, known as the forgiveness 
of the drug 49.  
 
Critically, the ABC taxonomy, which has not been applied extensively in either TB or asthma, 
allows stakeholders across disciplines to use a unified and standardised language to aid in the 
reporting of medication adherence.  There has been no impact study reporting its use; however, its 
uptake has been particularly prompted by its promotion within the International Society for 
Medication Adherence (ESPACOMP; formerly known as the European Society for Patient 
Adherence, Compliance, and Persistence ) Medication Adherence Reporting Guidelines 
(EMERGE) 145 in 2018.  For both conditions, the use of a standardised framework coupled with 
the granular data that is becoming increasingly available through DATs/EMDs could prove a 
game-changer in how we assess adherence globally. 
 
Due to the breadth of the scope of the review’s investigation, it was not feasible to conduct a 
systematic review of every paper relating to, or discussing, adherence in TB and asthma.  Where 
possible, we have cited systematic reviews in specific sub-areas of the paper, such as the Engelkes 
et al. review of studies measuring the association between adherence and risk of asthma attacks 7, 
and the Subbaraman et al. review of DATs used to measure adherence to anti-TB treatment 116.  
We have also carefully reviewed recent papers which have cited the ABC taxonomy paper, in order 




adherence research that we have not described.   
 
There is still considerable work to be done in improving adherence measurement and reporting.  
The lessons we can learn from other conditions can be synthesised to define the knowledge gaps 
and aspirations of the adherence field, for all stakeholders.   For clinicians, a detailed understanding 
of individual patient adherence and the associated risks will promote better advised treatment 
plans.  For patients, research into acceptability and effect of adherence measurement is crucial.  In 
clinical trials, knowledge about how adherence should be measured to best understand the 
relationship to clinical outcomes will allow better adjustment for patient adherence and better 
projections about expected prevalence of adverse events 146.  Finally, researchers must learn to 
most efficiently use systematic and consistent data sources such as medical records and DATs.   
 
By contrasting and comparing the measurement and reporting of medication adherence in two 
long-term respiratory diseases, one infectious (asthma) and the other non-infectious (TB), we 
provide further evidence for the benefits of the standardised terminologies and practices detailed 
in the ABC taxonomy and EMERGE guidelines when addressing this global issue for medication 
effectiveness. Health researchers can improve the value and generalisability of research across all 
health conditions by applying the proposed systematic approach to the measurement and reporting 
of adherence.  Consistent use of the taxonomy also promotes the conceptualisation of non-
adherence as a dynamic process, encouraging health professionals to explore the issue with 
patients during treatment, improving the consistency of dialogue between the health care providers 
a patient encounters, and providing guidance in the deployment of interventions: both clinical trials 
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